Clinical Trials Logo

Filter by:
NCT ID: NCT00910910 Completed - Clinical trials for B-Cell Chronic Lymphocytic Leukemia

Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)

ORIGIN
Start date: October 13, 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of lenalidomide as a first line therapy in treating patients with B-cell Chronic Lymphocytic Leukemia. This study will compare the effects (good and bad) of lenalidomide with chlorambucil.

NCT ID: NCT00910871 Completed - Tuberculosis Clinical Trials

To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.

Start date: September 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and effectiveness of TMC207 in combination with an individualized background regimen (BR) of antibacterial drugs as treatment for MDR-TB

NCT ID: NCT00910520 Completed - Overactive Bladder Clinical Trials

Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

Start date: September 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.

NCT ID: NCT00910429 Completed - Clinical trials for Pulmonary Hypertension

BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension

CHEST-2
Start date: July 1, 2009
Phase: Phase 3
Study type: Interventional

Patients who have completed the 16 weeks treatment of the CHEST-1 trial (study number 11348) will be asked to participate in this long term extension study with BAY63-2521. The aim of the long term study is to collect additional information to evaluate the safety and tolerability of BAY63-2521. Patients will be treated with open label medication on their individual optimal dose between 0,5 mg - 2,5 mg tid.

NCT ID: NCT00910091 Completed - Endometrial Cancer Clinical Trials

The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer

Start date: August 2009
Phase: Phase 2
Study type: Interventional

This trial will explore the safety and efficacy of BN83485 compared to Megestrol Acetate (MA) on progression free survival (PFS) in post menopausal patients with endometrial cancer.

NCT ID: NCT00910065 Completed - Clinical trials for Acute Coronary Syndrome

BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)

ACUTE
Start date: March 2011
Phase: Phase 3
Study type: Interventional

The objective of this study is to investigate whether intravenous administration (injected into a vein) of acetylsalicylic acid (Aspirin) in doses of 250 and 500 mg is superior to oral treatment of ACS with tablets containing 300 mg of Aspirin.

NCT ID: NCT00909597 Completed - Clinical trials for Diabetes Mellitus Type 2

A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes

Start date: May 2009
Phase: Phase 3
Study type: Interventional

This double-blind, double-dummy 3 arm study will evaluate the efficacy, safety and tolerability of taspoglutide versus pioglitazone in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea monotherapy or sulfonylurea plus metformin combination therapy. After an initial screening period, patients will be randomized to one of 3 groups, to receive a)taspoglutide 10mg sc weekly, b)taspoglutide 20mg sc weekly after 4 weeks of taspoglutide 10mg sc weekly or c)pioglitazone 45mg/day po after 4 weeks of pioglitazone 30mg/day po.The anticipated time on study treatment is 24 months, and the target sample size is 500+ individuals.

NCT ID: NCT00909051 Completed - Diabetes Mellitus Clinical Trials

GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups

Start date: March 24, 2009
Phase:
Study type: Observational

Evaluation of safety and effectiveness of Glucobay® under daily-life treatment conditions in a large sample of patients.

NCT ID: NCT00908349 Completed - Partial Epilepsy Clinical Trials

Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy

Start date: June 2009
Phase: Phase 3
Study type: Interventional

Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR)

NCT ID: NCT00907296 Completed - Fracture Healing Clinical Trials

Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing

STARTT
Start date: September 2, 2009
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to investigate the effect of romosozumab compared with placebo on time to radiographic healing of fresh tibial diaphyseal fractures (fractures in the midsection of the shinbone).